Huiqiong Zeng
Research Subjects
Research Interests
Huiqiong Zeng has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Baiwei Luo
Shenzhen Futian Hospital for Rheumatic Diseases
2 shared publicationsKaixia Zhou
Fudan University
2 shared publicationsShuai Chen
Yunnan University of Traditional Chinese Medicine
2 shared publicationsXia Huang
Department of Rheumatology, Shenzhen Futian Hospital for Rheumatic Diseases, Futian District, Shenzhen, Guangdong, China
2 shared publicationsH. -J. Liu
Guangdong Pharmaceut Assoc, Dept Safety Supervis Div, Guangzhou, Peoples R China
1 shared publicationHaiyan Peng
Department of Rheumatology, Shenzhen Futian Hospital for Rheumatic Diseases, Futian District, Shenzhen, Guangdong, China
1 shared publication
Latest Publications
- Open Access
- 21 May 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1394438
Genetic associations in ankylosing spondylitis: circulating proteins as drug targets and biomarkers
Background: Ankylosing spondylitis (AS) is a complex condition with a significant genetic component. This study explored circulating proteins as potential genetic drug targets or biomarkers to prevent AS, addressing the need for innovative and safe treatments.Methods: We analyzed extensive data from protein quantitative trait loci (pQTLs) with up to 1,949 instrumental variables (IVs) and selected the top single-nucleotide polymorphism (SNP) associated with AS risk. Utilizing a two-sample Mendelian randomization (MR) approach, we assessed the causal relationships between identified proteins and AS risk. Colocalization analysis, functional enrichment, and construction of protein-protein interaction networks further supported these findings. We utilized phenome-wide MR (phenMR) analysis for broader validation and repurposing of drugs targeting these proteins. The Drug-Gene Interaction database (DGIdb) was employed to corroborate drug associations with potential therapeutic targets. Additionally, molecular docking (MD) techniques were applied to evaluate the interaction between target protein and four potential AS drugs identified from the DGIdb.Results: Our analysis identified 1,654 plasma proteins linked to AS, with 868 up-regulated and 786 down-regulated. 18 proteins (AGER, AIF1, ATF6B, C4A, CFB, CLIC1, COL11A2, ERAP1, HLA-DQA2, HSPA1L, IL23R, LILRB3, MAPK14, MICA, MICB, MPIG6B, TNXB, and VARS1) that show promise as therapeutic targets for AS or biomarkers, especially MAPK14, supported by evidence of colocalization. PhenMR analysis linked these proteins to AS and other diseases, while DGIdb analysis identified potential drugs related to MAPK14. MD analysis indicated strong binding affinities between MAPK14 and four potential AS drugs, suggesting effective target-drug interactions.Conclusion: This study underscores the utility of MR analysis in AS research for identifying biomarkers and therapeutic drug targets. The involvement of Th17 cell differentiation-related proteins in AS pathogenesis is particularly notable. Clinical validation and further investigation are essential for future applications.
- 21 May 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1394438
Open AccessGenetic associations in ankylosing spondylitis: circulating proteins as drug targets and biomarkers
Background: Ankylosing spondylitis (AS) is a complex condition with a significant genetic component. This study explored circulating proteins as potential genetic drug targets or biomarkers to prevent AS, addressing the need for innovative and safe treatments.Methods: We analyzed extensive data from protein quantitative trait loci (pQTLs) with up to 1,949 instrumental variables (IVs) and selected the top single-nucleotide polymorphism (SNP) associated with AS risk. Utilizing a two-sample Mendelian randomization (MR) approach, we assessed the causal relationships between identified proteins and AS risk. Colocalization analysis, functional enrichment, and construction of protein-protein interaction networks further supported these findings. We utilized phenome-wide MR (phenMR) analysis for broader validation and repurposing of drugs targeting these proteins. The Drug-Gene Interaction database (DGIdb) was employed to corroborate drug associations with potential therapeutic targets. Additionally, molecular docking (MD) techniques were applied to evaluate the interaction between target protein and four potential AS drugs identified from the DGIdb.Results: Our analysis identified 1,654 plasma proteins linked to AS, with 868 up-regulated and 786 down-regulated. 18 proteins (AGER, AIF1, ATF6B, C4A, CFB, CLIC1, COL11A2, ERAP1, HLA-DQA2, HSPA1L, IL23R, LILRB3, MAPK14, MICA, MICB, MPIG6B, TNXB, and VARS1) that show promise as therapeutic targets for AS or biomarkers, especially MAPK14, supported by evidence of colocalization. PhenMR analysis linked these proteins to AS and other diseases, while DGIdb analysis identified potential drugs related to MAPK14. MD analysis indicated strong binding affinities between MAPK14 and four potential AS drugs, suggesting effective target-drug interactions.Conclusion: This study underscores the utility of MR analysis in AS research for identifying biomarkers and therapeutic drug targets. The involvement of Th17 cell differentiation-related proteins in AS pathogenesis is particularly notable. Clinical validation and further investigation are essential for future applications.
- Open Access
- 17 August 2023
- Published by Springer Nature in Research Square
Unveiling Urinary Biomarkers, Crucial Genes, and Immune Infiltration in Lupus Nephritis Patients
Background This study was conducted to investigate the expression patterns and biological roles of urinary long non-coding RNAs (lncRNAs) and messenger RNAs (mRNAs) in individuals diagnosed with lupus nephritis (LN). Methods The study cohort comprised six participants: three with systemic lupus erythematosus (SLE) involving LN, three with SLE without LN, and three healthy controls (CON). Microarray technology was employed to analyze urinary mRNAs and lncRNAs, thereby exploring alterations in overall RNA expression. Functional insights into dysregulated differentially expressed mRNAs (DEMs) associated with LN were derived through gene ontology (GO) enrichment analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, and gene set enrichment analysis (GSEA). Furthermore, the construction of a protein-protein interaction (PPI) network was accomplished using the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING). The identification of immune-related cell types was facilitated by Single-sample Gene Set Enrichment Analysis (ssGSEA). To predict potential drug candidates based on differentially expressed genes (DEGs), Connectivity Map (CMap) analysis was conducted. Results Within the urine samples of SLE patients, a total of 247 mRNAs and 602 lncRNAs exhibited differential expression relative to the control group. Among these, 83 down-regulated and 141 up-regulated DEMs were specifically discerned in patients with LN. GO analysis of the network highlighted enrichment in processes such as transcriptional regulation, intrinsic apoptotic signaling pathways in response to DNA damage, and the regulation of mitophagy. KEGG pathway analysis primarily revealed enrichment in protein processing within the endoplasmic reticulum, apoptosis, and the P53 signaling pathway. Co-expression and PPI network analysis suggested that nodes with higher degrees of connectivity were concentrated in pathways related to apoptosis and autophagy. An assessment of immune infiltration unveiled a correlation between activated B cells and CD56dim natural killer (NK) cells with LN pathogenesis. The prediction of drugs implicated inhibition of mechanistic Aurora kinase A (AURKA) as a primary targeted intervention. The molecular docking process confirmed the robust binding activity of hub genes' components. Conclusion This study has illuminated the distinct expression profiles of urinary long non-coding RNAs (lncRNAs) and messenger RNAs (mRNAs) in lupus nephritis (LN) patients. These profiles, particularly in the context of apoptosis, autophagy, and immune cell involvement, provide valuable insights into LN's underlying mechanisms. The identification of potential therapeutic targets, such as mechanistic AURKA, offers promising directions for future interventions in LN management.
- 17 August 2023
- Published by Springer Nature in Research Square
Open AccessUnveiling Urinary Biomarkers, Crucial Genes, and Immune Infiltration in Lupus Nephritis Patients
Background This study was conducted to investigate the expression patterns and biological roles of urinary long non-coding RNAs (lncRNAs) and messenger RNAs (mRNAs) in individuals diagnosed with lupus nephritis (LN). Methods The study cohort comprised six participants: three with systemic lupus erythematosus (SLE) involving LN, three with SLE without LN, and three healthy controls (CON). Microarray technology was employed to analyze urinary mRNAs and lncRNAs, thereby exploring alterations in overall RNA expression. Functional insights into dysregulated differentially expressed mRNAs (DEMs) associated with LN were derived through gene ontology (GO) enrichment analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, and gene set enrichment analysis (GSEA). Furthermore, the construction of a protein-protein interaction (PPI) network was accomplished using the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING). The identification of immune-related cell types was facilitated by Single-sample Gene Set Enrichment Analysis (ssGSEA). To predict potential drug candidates based on differentially expressed genes (DEGs), Connectivity Map (CMap) analysis was conducted. Results Within the urine samples of SLE patients, a total of 247 mRNAs and 602 lncRNAs exhibited differential expression relative to the control group. Among these, 83 down-regulated and 141 up-regulated DEMs were specifically discerned in patients with LN. GO analysis of the network highlighted enrichment in processes such as transcriptional regulation, intrinsic apoptotic signaling pathways in response to DNA damage, and the regulation of mitophagy. KEGG pathway analysis primarily revealed enrichment in protein processing within the endoplasmic reticulum, apoptosis, and the P53 signaling pathway. Co-expression and PPI network analysis suggested that nodes with higher degrees of connectivity were concentrated in pathways related to apoptosis and autophagy. An assessment of immune infiltration unveiled a correlation between activated B cells and CD56dim natural killer (NK) cells with LN pathogenesis. The prediction of drugs implicated inhibition of mechanistic Aurora kinase A (AURKA) as a primary targeted intervention. The molecular docking process confirmed the robust binding activity of hub genes' components. Conclusion This study has illuminated the distinct expression profiles of urinary long non-coding RNAs (lncRNAs) and messenger RNAs (mRNAs) in lupus nephritis (LN) patients. These profiles, particularly in the context of apoptosis, autophagy, and immune cell involvement, provide valuable insights into LN's underlying mechanisms. The identification of potential therapeutic targets, such as mechanistic AURKA, offers promising directions for future interventions in LN management.
- Open Access
- 22 June 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1179664
Exploring the potential common denominator pathogenesis of system lupus erythematosus with COVID-19 based on comprehensive bioinformatics analysis
Objective: Evidences show that there may be a link between SLE and COVID-19. The purpose of this study is to screen out the diagnostic biomarkers of systemic lupus erythematosus (SLE) with COVID-19 and explore the possible related mechanisms by the bioinformatics approach.Methods: SLE and COVID-19 datasets were extracted separately from the NCBI Gene Expression Omnibus (GEO) database. The limma package in R was used to obtain the differential genes (DEGs). The protein interaction network information (PPI) and core functional modules were constructed in the STRING database using Cytoscape software. The hub genes were identified by the Cytohubba plugin, and TF-gene together with TF-miRNA regulatory networks were constructed via utilizing the Networkanalyst platform. Subsequently, we generated subject operating characteristic curves (ROC) to verify the diagnostic capabilities of these hub genes to predict the risk of SLE with COVID-19 infection. Finally, a single-sample gene set enrichment (ssGSEA) algorithm was used to analyze immune cell infiltration.Results: A total of 6 common hub genes (CDC6, PLCG1, KIF15, LCK, CDC25C, and RASGRP1) were identified with high diagnostic validity. These gene functional enrichments were mainly involved in cell cycle, and inflammation-related pathways. Compared to the healthy controls, abnormal infiltration of immune cells was found in SLE and COVID-19, and the proportion of immune cells linked to the 6 hub genes.Conclusion: Our research logically identified 6 candidate hub genes that could predict SLE complicated with COVID-19. This work provides a foothold for further study of potential pathogenesis in SLE and COVID-19.
- 22 June 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1179664
Open AccessExploring the potential common denominator pathogenesis of system lupus erythematosus with COVID-19 based on comprehensive bioinformatics analysis
Objective: Evidences show that there may be a link between SLE and COVID-19. The purpose of this study is to screen out the diagnostic biomarkers of systemic lupus erythematosus (SLE) with COVID-19 and explore the possible related mechanisms by the bioinformatics approach.Methods: SLE and COVID-19 datasets were extracted separately from the NCBI Gene Expression Omnibus (GEO) database. The limma package in R was used to obtain the differential genes (DEGs). The protein interaction network information (PPI) and core functional modules were constructed in the STRING database using Cytoscape software. The hub genes were identified by the Cytohubba plugin, and TF-gene together with TF-miRNA regulatory networks were constructed via utilizing the Networkanalyst platform. Subsequently, we generated subject operating characteristic curves (ROC) to verify the diagnostic capabilities of these hub genes to predict the risk of SLE with COVID-19 infection. Finally, a single-sample gene set enrichment (ssGSEA) algorithm was used to analyze immune cell infiltration.Results: A total of 6 common hub genes (CDC6, PLCG1, KIF15, LCK, CDC25C, and RASGRP1) were identified with high diagnostic validity. These gene functional enrichments were mainly involved in cell cycle, and inflammation-related pathways. Compared to the healthy controls, abnormal infiltration of immune cells was found in SLE and COVID-19, and the proportion of immune cells linked to the 6 hub genes.Conclusion: Our research logically identified 6 candidate hub genes that could predict SLE complicated with COVID-19. This work provides a foothold for further study of potential pathogenesis in SLE and COVID-19.
- 1 January 2023
- Vol. 27 (16) , 7459-7469
Assessment of hesitancy to COVID-19 vaccine in patients with rheumatic arthritis
OBJECTIVE: The COVID-19 pandemic caused by SARS-CoV-2 in 2019 has greatly impacted global health, leading to high morbidity and mortality rates. Rheumatoid arthritis (RA) patients have faced numerous challenges during the pandemic, including concerns about infection, limited medical resources, and shortages of medication. While vaccination is a crucial strategy against COVID-19, the reasons behind vaccine hesitancy (VH) among people with RA remain largely unexplored. SUBJECTS AND METHODS: We conducted a cross-sectional, single-arm study in China from July 18 to August 18, 2021. Using a self-administered questionnaire and a convenient sampling method, we investigated vaccine attitudes and VH among RA patients. The questionnaire developed by the investigators was validated by two public health experts and one senior rheumatologist. It covered sociodemographics, disease-related variables, vaccination attitudes, and willingness, etc. We employed Chi-squared and regression analyses to identify factors associated with VH toward COVID-19 vaccination. RESULTS: A total of 184 RA patients were enrolled in the survey, with 113 (61.41%) expressing unwillingness to be vaccinated. The Chi-squared test revealed significant differences in employment status and related systemic damage (p < 0.05). Among the unvaccinated RA patients, 71.68% believed COVID-19 vaccination might impact their disease. Binary and multicollinearity logistic regression analyses showed that the acute stage of RA (p < 0.001, OR = -3.165, 95% CI: 0.035 - 0.164) and fear of disease development caused by drug discontinuation during vaccination (p < 0.001, OR = -3.591, 95% CI: 0.005 0.157) were the restricting factors influencing the COVID-19 vaccine inoculation rate in RA patients. CONCLUSIONS: The COVID-19 vaccination rate among RA patients in China is low due to limited knowledge, misconceptions, and insufficient promotion. Boosting confidence and understanding of the vaccine's effectiveness and safety is crucial to improve vaccination success.
- 1 January 2023
- Vol. 27 (16) , 7459-7469
Assessment of hesitancy to COVID-19 vaccine in patients with rheumatic arthritis
OBJECTIVE: The COVID-19 pandemic caused by SARS-CoV-2 in 2019 has greatly impacted global health, leading to high morbidity and mortality rates. Rheumatoid arthritis (RA) patients have faced numerous challenges during the pandemic, including concerns about infection, limited medical resources, and shortages of medication. While vaccination is a crucial strategy against COVID-19, the reasons behind vaccine hesitancy (VH) among people with RA remain largely unexplored. SUBJECTS AND METHODS: We conducted a cross-sectional, single-arm study in China from July 18 to August 18, 2021. Using a self-administered questionnaire and a convenient sampling method, we investigated vaccine attitudes and VH among RA patients. The questionnaire developed by the investigators was validated by two public health experts and one senior rheumatologist. It covered sociodemographics, disease-related variables, vaccination attitudes, and willingness, etc. We employed Chi-squared and regression analyses to identify factors associated with VH toward COVID-19 vaccination. RESULTS: A total of 184 RA patients were enrolled in the survey, with 113 (61.41%) expressing unwillingness to be vaccinated. The Chi-squared test revealed significant differences in employment status and related systemic damage (p < 0.05). Among the unvaccinated RA patients, 71.68% believed COVID-19 vaccination might impact their disease. Binary and multicollinearity logistic regression analyses showed that the acute stage of RA (p < 0.001, OR = -3.165, 95% CI: 0.035 - 0.164) and fear of disease development caused by drug discontinuation during vaccination (p < 0.001, OR = -3.591, 95% CI: 0.005 0.157) were the restricting factors influencing the COVID-19 vaccine inoculation rate in RA patients. CONCLUSIONS: The COVID-19 vaccination rate among RA patients in China is low due to limited knowledge, misconceptions, and insufficient promotion. Boosting confidence and understanding of the vaccine's effectiveness and safety is crucial to improve vaccination success.
- Open Access
- 2 December 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 1059887
Novel insight into miRNA biology and its role in the pathogenesis of systemic lupus erythematosus
MicroRNAs(miRNAs) have emerged as key regulators that control and influence gene expression as well as multiple biological processes depending on their potential binding sites in human-protein coding genes and other unconventional patterns, including coding for peptides, activating Toll-like receptors as a ligand, and other manners. Accumulating evidence has demonstrated that microRNA expression is tightly regulated during phases of development, differentiation, and effector functions of immune cells, immunological disorders of systemic lupus erythematosus (SLE). This review outlines the biogenesis of miRNAs and their unconventional functions as well as underlying cellular and molecular mechanisms. It then summarizes our current knowledge about how the biogenesis of miRNAs is regulated. Moreover, an overview was provided concerning the role of abnormal expression of miRNAs in lupus immune cells. In particular, we will shed some light on the recent advances in the role of miRNAs and exosome-derived miRNAs in immunological and epigenetic pathways in the pathogenesis of SLE.
- 2 December 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 1059887
Open AccessNovel insight into miRNA biology and its role in the pathogenesis of systemic lupus erythematosus
MicroRNAs(miRNAs) have emerged as key regulators that control and influence gene expression as well as multiple biological processes depending on their potential binding sites in human-protein coding genes and other unconventional patterns, including coding for peptides, activating Toll-like receptors as a ligand, and other manners. Accumulating evidence has demonstrated that microRNA expression is tightly regulated during phases of development, differentiation, and effector functions of immune cells, immunological disorders of systemic lupus erythematosus (SLE). This review outlines the biogenesis of miRNAs and their unconventional functions as well as underlying cellular and molecular mechanisms. It then summarizes our current knowledge about how the biogenesis of miRNAs is regulated. Moreover, an overview was provided concerning the role of abnormal expression of miRNAs in lupus immune cells. In particular, we will shed some light on the recent advances in the role of miRNAs and exosome-derived miRNAs in immunological and epigenetic pathways in the pathogenesis of SLE.
- Open Access
- 13 September 2022
- Published by Frontiers Media SA in Frontiers in Bioinformatics
- Vol. 2
Investigating the molecular mechanism of iguratimod act on SLE using network pharmacology and molecular docking analysis
Objective: Iguratimod (IGU) is a novel small disease-modifying compound widely used in Asia for the treatment of rheumatic diseases. IGU is a methane sulfonanilide. We applied network pharmacology to investigate the pharmacological mechanisms of IGU act on SLE.Methods: We used PharmMapper, UniProt, and OMIM databases to screen the potential targets of IGU, and the SLE-related disease targets were predicted. Hub target genes among the intersections of the potential targets (IGU) and related genes (SLE) were validated using the PPI network generated by the String database. GO and KEGG enrichment analyses were carried out using the David online platform. Finally, the molecular docking of hub targets and their corresponding compounds were completed through AutoDock Vina and PyMOL software for visualization.Result: A total of 292 potential targets of IGU, 6501 related disease targets of SLE, and 114 cross targets were screened from the aforementioned database. Network topology analysis identified 10 hub targets, such as CASP3, AKT1, EGFR, MMP9, and IGF1. GO enrichment analysis mainly focuses on the negative regulation of the apoptotic process and signal transduction. KEGG enrichment analysis illustrated that the PI3K-AKT signaling pathway, MAPK signaling pathway, and FoxO signaling pathway might play a significant role in the pharmacological mechanisms of IGU act on SLE. Molecular docking confirmed that the IGU ligand had strong binding activity to the hub targets.Conclusion: This study based on network pharmacology and molecular docking validation preliminarily revealed the protein targets affected by IGU acting on SLE through, and explored potential therapeutic mechanism role of IGU in SLE treatment by multi pathways.
- 13 September 2022
- Published by Frontiers Media SA in Frontiers in Bioinformatics
- Vol. 2
Open AccessInvestigating the molecular mechanism of iguratimod act on SLE using network pharmacology and molecular docking analysis
Objective: Iguratimod (IGU) is a novel small disease-modifying compound widely used in Asia for the treatment of rheumatic diseases. IGU is a methane sulfonanilide. We applied network pharmacology to investigate the pharmacological mechanisms of IGU act on SLE.Methods: We used PharmMapper, UniProt, and OMIM databases to screen the potential targets of IGU, and the SLE-related disease targets were predicted. Hub target genes among the intersections of the potential targets (IGU) and related genes (SLE) were validated using the PPI network generated by the String database. GO and KEGG enrichment analyses were carried out using the David online platform. Finally, the molecular docking of hub targets and their corresponding compounds were completed through AutoDock Vina and PyMOL software for visualization.Result: A total of 292 potential targets of IGU, 6501 related disease targets of SLE, and 114 cross targets were screened from the aforementioned database. Network topology analysis identified 10 hub targets, such as CASP3, AKT1, EGFR, MMP9, and IGF1. GO enrichment analysis mainly focuses on the negative regulation of the apoptotic process and signal transduction. KEGG enrichment analysis illustrated that the PI3K-AKT signaling pathway, MAPK signaling pathway, and FoxO signaling pathway might play a significant role in the pharmacological mechanisms of IGU act on SLE. Molecular docking confirmed that the IGU ligand had strong binding activity to the hub targets.Conclusion: This study based on network pharmacology and molecular docking validation preliminarily revealed the protein targets affected by IGU acting on SLE through, and explored potential therapeutic mechanism role of IGU in SLE treatment by multi pathways.